Kazunari Sekiyama

Dr. Kazunari Sekiyama


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MWMasaaki Waragai
Masaaki Waragai
KSKazunari Sekiyama
Kazunari Sekiyama
ASAkio Sekigawa
Akio Sekigawa
YTYoshiki Takamatsu
Yoshiki Takamatsu
MFMasayo Fujita
Masayo Fujita
MHMakoto Hashimoto
Makoto Hashimoto
Parkinson’s disease (PD) is the most common form of movement disorder and affects approximately 4% of the population aged over 80 years old. Currently, PD cannot be prevented or cured, and no single diagnostic biomarkers are available. Notably, recent studies suggest that two familial PD-linked molecules, α-synuclein and DJ-1, are present in cerebrospinal fluid (CSF) and that their levels may be altered during the progression of PD. In this regard, sensitive and accurate methods for evaluation of α-synuclein and DJ-1 levels in the CSF and blood have been developed, and the results suggest that the levels of both molecules are significantly decreased in the CSF in patients with PD compared with age-matched controls. Furthermore, specific detection and quantification of neurotoxic oligometric forms of α-synuclein in the blood using enzyme-linked immunosorbent assays might be expected as potential peripheral biomarkers for PD, although further validation is required. Currently, neither α-synuclein nor DJ-1 is satisfactory as a single biomarker for PD, but combinatory evaluation of these biological fluid molecules with other biomarkers and imaging techniques may provide reliable information for diagnosis of PD.

11 March 2011 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
TTTakato Takenouchi
Takato Takenouchi
YIYoshifumi Iwamaru
Yoshifumi Iwamaru
SSShuei Sugama
Shuei Sugama
MTMitsutoshi Tsukimoto
Mitsutoshi Tsukimoto
MFMasayo Fujita
Masayo Fujita
HKHiroshi Kitani
Hiroshi Kitani
J. Neurochem. (2011) 117, 712–723. Abstract The potent pro‐inflammatory cytokine, interleukin‐1β (IL‐1β), is synthesized as an inactive 33‐kDa precursor (pro‐IL‐1β) and is processed by caspase 1 into the bioactive 17‐kDa mature form. The P2X7 receptor, an ATP‐gated cation channel, plays an essential role in caspase 1 activation, production and release of mature bioactive 17‐kDa form. We recently reported ATP induces the release of an unconventional 20‐kDa form of IL‐1β (p20‐IL‐1β) from lipopolysaccharide‐primed microglial cells. Emerging evidence suggests physiological relevance for p20‐IL‐1β; however, the underlying mechanisms for its production and release remain unknown. Here, we investigated the pathways involved in the ATP‐induced production of p20‐IL‐1β using lipopolysaccharide‐primed mouse microglial cells. The activation of P2X7 receptor by ATP triggered p20‐IL‐1β production under acidic extracellular conditions. ATP‐induced p20‐IL‐1β production was blocked by pepstatin A, a potent inhibitor of the lysosomal protease, cathepsin D. The removal of extracellular Ca2+ inhibited the p20‐IL‐1β production as well as ATP‐induced cathepsin D release via lysosome exocytosis. The acidic extracellular pH also facilitated the dilatation of membrane pore after ATP stimulation. Since facilitation of pore dilatation results in cytolysis accompanied with cytoplasmic pro‐IL‐1β leakage, our data suggest the leaked pro‐IL‐1β is processed into p20‐IL‐1β by cathepsin D released after ATP stimulation under acidic extracellular conditions.

26 September 2012 in Molecular Brain
Verified
Journal Article
Open access
PDF file
ASAkio Sekigawa
Akio Sekigawa
MFMasayo Fujita
Masayo Fujita
KSKazunari Sekiyama
Kazunari Sekiyama
YTYoshiki Takamatsu
Yoshiki Takamatsu
THTaku Hatano
Taku Hatano
MHMakoto Hashimoto
Makoto Hashimoto
Background: Axonopathy is critical in the early pathogenesis of neurodegenerative diseases, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Axonal swellings such as globules and spheroids are a distinct feature of axonopathy and our recent study showed that transgenic (tg) mice expressing DLB-linked P123H β-synuclein (P123H βS) were characterized by P123H βS-immunoreactive axonal swellings (P123H βS-globules). Therefore, the objectives of this study were to evaluate α-synuclein (αS)-immunoreactive axonal swellings (αS-globules) in the brains of tg mice expressing human wild-type αS and to compare them with the globules in P123H βS tg mice. Results: In αS tg mice, αS-globules were formed in an age-dependent manner in various brain regions, including the thalamus and basal ganglia. These globules were composed of autophagosome-like membranous structures and were reminiscent of P123H βS-globules in P123H βS tg mice. In the αS-globules, frequent clustering and deformation of mitochondria were observed. These changes were associated with oxidative stress, based on staining of nitrated αS and 4-hydroxy-2-nonenal (4-HNE). In accord with the absence of mitochondria in the P123H βS-globules, staining of nitrated αS and 4-HNE in these globules was weaker than that for αS-globules. Leucine-rich repeat kinase 2 (LRRK2), the PARK8 of familial PD, was detected exclusively in αS-globules, suggesting a specific role of this molecule in these globules. Conclusions: Lysosomal pathology was similarly observed for both αS- and P123H βS-globules, while oxidative stress was associated with the αS-globules, and to a lesser extent with the P123H βS-globules. Other pathologies, such as mitochondrial alteration and LRRK2 accumulation, were exclusively detected for αS-globules. Collectively, both αS- and P123H βS-globules were formed through similar but distinct pathogenic mechanisms. Our findings suggest that synuclein family members might contribute to diverse axonal pathologies.

19 May 2015 in Biomolecules
Verified
Journal Article
Open access
PDF file
ASAkio Sekigawa
Akio Sekigawa
YTYoshiki Takamatsu
Yoshiki Takamatsu
KSKazunari Sekiyama
Kazunari Sekiyama
MHMakoto Hashimoto
Makoto Hashimoto
Axonal swellings are histological hallmarks of axonopathies in various types of disorders in the central nervous system, including neurodegenerative diseases. Given the pivotal role of axonopathies during the early phase of neurodegenerative process, axonal swellings may be good models which may provide some clues for early pathogenesis of α-synucleinopathies, including Parkinson’s disease and dementia with Lewy bodies (DLB). In this mini-review, such a possibility is discussed based on our recent studies as well as other accumulating studies. Consistent with the current view that dysfunction in the autophagy-lysosomal system may play a major role in the formation of axonal swellings, our studies showed globule, small axonal swellings, derived from transgenic mice expressing either human wild-type α-synuclein (αS-globule) or DLB-linked P123H β-synuclein (βS-globule), contained autophagosome-like membranes. However, other pathological features, such as abnormal mitochondria, enhanced oxidative stress and LRRK2 accumulation, were observed in the αS-globules, but not in the βS-globules. Collectively, it is predicted that αS and βS may be involved in axonopathies through similar but distinct mechanisms, and thus, contribute to diverse axonal pathologies. Further studies of the axonal swellings may lead to elucidating the pathogenic mechanism of early α-synucleinopathies and illuminating a strategy for a disease-modifying therapy against these devastating disorders.

Verified
Journal Article
Open access
PDF file
MFMasayo Fujita
Masayo Fujita
ASAkio Sekigawa
Akio Sekigawa
KSKazunari Sekiyama
Kazunari Sekiyama
YTYoshiki Takamatsu
Yoshiki Takamatsu
MHMakoto Hashimoto
Makoto Hashimoto
α-Synucleinopathies are neurodegenerative disorders that are characterized by progressive decline of motor and non-motor dysfunctions. α-Synuclein (αS) has been shown to play a causative role in neurodegeneration, but the pathogenic mechanisms are still unclear. Thus, there are no radical therapies that can halt or reverse the disease’s progression. β-Synuclein (βS), the non-amyloidogenic homologue of αS, ameliorates the neurodegeneration phenotype of αS in transgenic (tg) mouse models, as well as in cell free and cell culture systems, which suggests that βS might be a negative regulator of neurodegeneration caused by αS, and that “loss of function” of βS might be involved in progression of α-synucleinopathies. Alternatively, it is possible that “toxic gain of function” of wild type βS occurs during the pathogenesis of sporadic α-synucleinopathies, since tg mice expressing dementia with Lewy bodies-linked P123H βS develop progressive neurodegeneration phenotypes, such as axonal pathology and dementia. In this short review, we emphasize the aspects of “toxic gain of function” of wild type βS during the pathogenesis of sporadic α-synucleinopathies.

Verified
Journal Article
Open access
PDF file
MOMASATO OKITSU
MASATO OKITSU
MFMasayo Fujita
Masayo Fujita
YMYuki Moriya
Yuki Moriya
HKHiroko Kotajima-Murakami
Hiroko Kotajima-Murakami
SISoichiro Ide
Soichiro Ide
KIKazutaka Ikeda
Kazutaka Ikeda
Among the symptoms of Parkinson’s disease (PD), apathy comprises a set of behavioral, affective, and cognitive features that can be classified into several subtypes. However, the pathophysiology and brain regions that are involved in these different apathy subtypes are still poorly characterized. We examined which subtype of apathy is elicited in a mouse model of PD with 6-hydroxydopamine (6-OHDA) lesions and the behavioral symptoms that are exhibited. Male C57/BL6J mice were allocated to sham (n = 8) and 6-OHDA (n = 13) groups and locally injected with saline or 4 µg 6-OHDA bilaterally in the dorsal striatum. We then conducted motor performance tests and apathy-related behavioral experiments. We then pathologically evaluated tyrosine hydroxylase (TH) immunostaining. The 6-OHDA group exhibited significant impairments in motor function. In the behavioral tests of apathy, significant differences were observed between the sham and 6-OHDA groups in the hole-board test and novelty-suppressed feeding test. The 6-OHDA group exhibited impairments in inanimate novel object preference, whereas social preference was maintained in the three-chamber test. The number of TH+ pixels in the caudate putamen and substantia nigra compacta was significantly reduced in the 6-OHDA group. The present mouse model of PD predominantly showed dorsal striatum dopaminergic neuronal loss and a decrease in novelty seeking as a symptom that is related to the cognitive apathy component.